Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Belumosudil
Drug ID BADD_D02532
Description Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension.[A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC50 100 nM vs. 3 μM, respectively).[L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve immune dysregulation by shifting the balance between Th17 cells and T-regulatory cells, thereby dampening the inflammatory cascade that can occasionally be fatal.[A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines of systemic therapy.[L34754]
Indications and Usage Belumosudil is indicated for the treatment of chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years of age and older following failure of at least two other lines of systemic therapy.[L34749]
Marketing Status approved; investigational
ATC Code L04AA48
DrugBank ID DB16703
KEGG ID D11815
MeSH ID C000718240
PubChem ID 11950170
TTD Drug ID Not Available
NDC Product Code 69988-0056; 79802-200
UNII 834YJF89WO
Synonyms belumosudil | rezurock
Chemical Information
Molecular Formula C26H24N6O2
CAS Registry Number 911417-87-3
SMILES CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.001230%
Condition aggravated08.01.03.0040.000241%-
Death08.04.01.0010.000964%
Drug ineffective08.06.01.0060.001230%-
Dyspnoea02.11.05.003; 22.02.01.0040.000530%
Fatigue08.01.01.0020.000820%
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.0090.000362%-
Headache17.14.01.0010.001230%
Disease progression08.01.03.0380.000241%
The 1th Page    1    Total 1 Pages